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A B S T R A C T
During the last decade the process of introducing the new generation of antiepileptic
drugs (AEDs) has substantially changed the ways of treating epilepsy. Although a great
deal of information about the role of new drugs has been accumulated, much less atten-
tion was paid to the impact of the new generation of AEDs on the utilization of classical
AEDs. In order to detect the relation between the new and classical AEDs, the data
about drug consumption in Croatia in the period 2000–2002 were analyzed. The main
results indicated that the growth utilization rate (15%) was more the result of increas-
ing consumption of the classical antiepileptic substances (in almost 2/3). It has been dis-
cussed that one of the possible interpretations for this phenomenon could lie in the fact
that the continuing process of introducing the new AEDs was accompanied by a great
number of educational activities. These activities have led to greater awareness of the
facilities in treating epilepsy and consequently to a more active therapeutic approach,
which encompassed both generations of drugs, even more the older one.
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Introduction
At the end of the 20th century, several
new antiepileptic drugs (AEDs) were in-
troduced into therapeutic practice. Al-
though the exact role of the new drugs in
some aspects of the therapy is still con-
troversial1, their introduction has led to
substantial qualitative and quantitative
changes in the pattern of medication use.
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It is clear that the introduction of the new
AEDs has led to the substantial expand-
ing of the AEDs spectrum of use, but it is
not completely clear whether the conse-
quences on the consumption of traditio-
nal remedies could be the result of the in-
troduction of the new drugs. Monitoring
the drug utilization could be a useful tool
for assessing these changes.
The new AEDs have been registered
in Croatia in the following order: viga-
batrin (1996), lamotrigine (1999), topira-
mate (2000) and gabapentin (2002). As
the process of gradual introducing of new
AEDs is still under way, Croatia could be
a useful model for studying the relation-
ship between the traditional (»old«) and
new AEDs.
The purpose of this study is to deter-
mine the changes in AEDs utilization
which could be related to the process of
introducing new AEDs into antiepileptic
therapy.
Methods
Data obtained from the Croatian
Health Institute were used. The original
data consisted of the numbers of packs
and costs of the drugs for the periods
01/01/2000–31/09/2002. These data were
transformed into yearly values, and num-
bers of packs were expressed as numbers
of defined daily doses (DDD), as defined
by WHO Collaborating Centre for Drug
Statistics Methodology2. The drug utili-
zation was also expressed as the number
of DDD/1000 people, according to the cen-
sus carried out in the year 20013.
Results
In Figure 1 it is shown that the utili-
zation of AEDs in the year 2002 was dom-
inated by carbamezepine and the group of
barbiturates (phenobarbital, metilpheno-
barbital, primidon). The valproates (val-
proic acid and valpromide) were in the
third place, whereas other AEDs, includ-
ing the new AEDs, were substantially
less often prescribed.
The trend of growing utilization of
AEDs in the three-year period is demon-
strated in Figure 2. It can be seen that in
the year 2000 3.9 DDD were consumed
daily in the population of 1000 people,
and in the year 2002 this number reached
4.5 DDD, i.e., the increase was about 15%
in relation to the year 2000.
In Figure 3 it is demonstrated that the
increase of utilization was not only re-
lated to the increase of utilization of new
AEDs. Actually, what can be seen is the
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Fig. 1. Frequency of prescribed AEDs in 2002.
Abbreviations and DDD values used2 (in bra-
ckets): BARB – barbiturates: phenobarbital
(0.1 g), metylphenobarbital (0.5 g), primidon
(1.25 g), PHT – phenytoin (0.3 g), CBZ – car-
bamazepine (1 g), VPA – valproates: valproic
acid (1.5 g), valpromide (1.5 g), ESM – ethosu-
xinimyde (1.25 g), CLN – clonazepam (8 mg),
VGB – vigabatrin (2 g), LTG – lamotrigine (0.3










Fig. 2. Number of consumed DDD/1000 popu-
lation/day.
fact that in three previous years classical
AEDs increased their utilization more
than the new ones. The increase of the old
AEDs was about 600,000 DDD, and the
growth of the new AEDs was about
240,000 DDD.
Discussion
Antiepileptic drug utilization is one of
the main markers indicating the level of
management for people with epilepsy. The
biggest therapeutic gap is in the develop-
ing countries, but it has been reported in
Europe, too4–5. Consequently, an increase
in consumption of AEDs can be generally
interpreted as a positive fact.
In the last decade of the 20th century,
several new AEDs were introduced into
therapy worldwide. Among those widely
accepted are vigabatrin, lamotrigine, ga-
bapentin, oxcarbamazepine, felbamate,
tiagabine, zonisamide, topiramate, and
levetiracetam6. These drugs have some
advantages: some of them are better to-
lerated7–8, some of them have fewer inter-
action capacities9–10, plasma level is not
recommended for any of them11–12. Con-
cerning the efficacy of these drugs in com-
parison to the older ones, they are gener-
ally considered to have equal efficacy and
in some conditions are slightly more effi-
cacious13. In some epileptic syndromes,
however, they represent real progress
and a better chance for the cure of epi-
lepsy14–21. Because of the higher cost, the
question of the cost-effectiveness is still
controversial especially for the poorer, de-
veloping countries22–24.
Although a great deal of information
about the role of new AEDs in therapy
has been accumulated, much less atten-
tion was paid to the impact of the new
generation of AEDs on the utilization of
classical AEDs, such as barbiturates,
phenytoin, valproates and carbamazepi-
ne. Considering the substantial advan-
tages of the new medicines, one of the
possible results of gradual introducing of
new AEDs would be the substitution of
older drugs for the new, and potentially
better AEDs. This hypothesis was tested
in this study.
AEDs utilization was studied using
the methodology proposed by WHO Col-
laborating Centre for Drug Statistics Me-
thodology. This methodology is thought to
be a useful technique to make it possible
for the drug consumption data to be mea-
sured and compared, both nationally and
internationally25–27.
Our results indicated that the intro-
ducing of new AEDs did not result in the
simple substitution of classical AEDs for
the new ones. In the period of the last
three years it was observed that there
was a substantial increase of general con-
sumption of about 15% (year 2000 vs.
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Fig. 3. Increase of AEDs 2000–2002.
2002), but the more recent generation of
AEDs participated with only about 1/3 of
this figure. At first sight, these results
seem to be paradoxical, because it ap-
peared that the promotion of new AEDs
resulted in an even greater increase of
the AEDs which were intended to be re-
placed.
Apart from the promotional campaign
of the new AEDs, some populational fac-
tors might have influenced the general
increase of AED consumption. However,
there were no significant changes in the
population number in Croatia during the
period of research which could have influ-
enced the prevalence of epilepsy. More-
over, there were no changes in the access
to medical care or changes in the reim-
bursement (all AEDs are free of charge).
As a matter of fact, according to the best
of our knowledge, there was no increase
in AED utilization for other conditions
besides epilepsy, and there were no other
factors that could have influenced chan-
ges in the incidence of epilepsy.
There are no unambiguous answers
for the fact that traditional AEDs had a
greater share in the general utilization of
AEDs. Yet, a plausible explanation for
that phenomenon would be that the ap-
pearance of new AEDs in Croatia actu-
ally resulted in an apparently paradoxi-
cal increase in the consumption of the
traditional AEDs. We think that it was
caused by the intensive promotional cam-
paign, supported by pharmaceutical in-
dustries which resulted, among other is-
sues, in a series of meetings dealing with
the therapy of epilepsy. Those activities,
at least partly, were designed as educa-
tional courses focused on the target popu-
lation of physicians dealing with epilepsy,
especially neurologists and neuropaedia-
tricians*. It seems that the promotional
campaign organized in this way, which
has been continuing so far, has led to
greater awareness of the therapeutic fa-
cilities in treating epilepsy. Consequently,
the more active and more enthusiastic
therapeutic approach has been develop-
ed, which led to the greater utilization of
all AEDs, both of the new and old genera-
tions. As the classical drugs are much
more widely used in Croatia, the trend of
growing utilization expressed in absolute
figures affected the old generation of
drugs. If one would accept such an at-
tempt of interpretation, the growing utili-
zation of traditional AEDs could be re-
garded as a kind of distant secondary
effect of the introduction of the new an-
tiepileptics.
In conclusion, it seems that the trend
of growing utilization of the standard
AEDs could be related to the process of
introducing the new AEDs accompanied
by a great variety of educational activi-
ties. These activities have led to greater
awareness of the facilities in treating epi-
lepsy and consequently to a more active
therapeutic approach, which encompas-
sed both generations of drugs, even more
the older one. Although the above inter-
pretation might sound plausible, similar
studies in other countries are indispens-
able to confirm or reject the hypothesis
arrived at in this work.
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* In the period 2000–2002 the following meetings and educational courses dealing with the new AEDs were
held in Croatia: »The contemporary therapy of epilepsy« – organized by the Croatian league against epilepsy,
but with the contribution of the pharmaceutical industries (Zagreb – December 2000, 2001 and 2002), the
workshops about Topamax – organized by »Jansen-Cilag« (Zagreb – May 2001, June 2002, and Umag – May
2002)
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PORAST KORI[TENJA KLASI^NIH ANTIEPILEPTI^KIH LIJEKOVA
U HRVATSKOJ TIJEKOM PROCESA UVO\ENJA LIJEKOVA NOVE
GENERACIJE
S A @ E T A K
Tijekom posljednjeg desetlje}a proces uvo|enja nove generacije antiepilepti~kih li-
jekova (AEL) znatno je promjenio na~ine lije~enja epilepsije. Premda se do{lo do veli-
kog broja informacija o ulozi novih lijekova u lije~enju epilepsije, mnogo manje se zna o
utjecaju nove generacije AEL na kori{tenje klasi~nih AEL. S ciljem da se ustanove
odnosi izme|u novih i klasi~nih AEL, analizirani su podaci o kori{tenju tih lijekova u
Hrvatskoj u razdoblju od 2000. do 2002. godine. Rezultati su pokazali da je porast ko-
ri{tenja (15%) vi{e bio izraz porasta potro{nje klasi~nih antiepileptika (gotovo 2/3). U
raspravi je nagla{eno da jedna od mogu}ih interpretacija tog fenomena mo`e biti u
tome {to je kontinuirani proces uvo|enja novih AEL bio pra}en nizom edukativnih ak-
tivnosti koje su dovele do vi{e razine znanja o mogu}nostima lije~enja epilepsije. Po-
sljedi~no tome, aktivniji stav pri lije~enju doveo je do porasta kori{tenja obje generacije
lijekova, {tovi{e, u ve}oj mjeri klasi~nih AEL.
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